Aequus Pharmaceuticals Inc. (CVE:AQS – Get Free Report) hit a new 52-week low on Tuesday . The stock traded as low as C$0.01 and last traded at C$0.01, with a volume of 7000 shares traded. The stock had previously closed at C$0.01.
Aequus Pharmaceuticals Stock Performance
The firm has a market capitalization of C$663,150.00, a PE ratio of -0.50 and a beta of -0.02. The business has a 50-day simple moving average of C$0.01 and a 200-day simple moving average of C$0.01. The company has a debt-to-equity ratio of 138.88, a current ratio of 0.07 and a quick ratio of 0.46.
Aequus Pharmaceuticals Company Profile
Aequus Pharmaceuticals Inc operates as a specialty pharmaceutical company in Canada. The company markets ZIMED PF, a preservative-free bimatoprost ophthalmic solution. It also develops a range of prescription-free dry eye products under the OPTASE name; and REV-0100 for the treatment of stargardt disease.
Recommended Stories
- Five stocks we like better than Aequus Pharmaceuticals
- What is a Dividend King?
- Cerence AI: One-Hit Wonder or Long-Term Winner After NVIDIA Pact?
- What Does a Gap Up Mean in Stocks? How to Play the Gap
- UnitedHealth Group Pulls Back Into Another Healthy Opportunity
- How Investors Can Find the Best Cheap Dividend Stocks
- Micron Technology: Riding the AI Wave to Long-Term Growth
Receive News & Ratings for Aequus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aequus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
